PET–Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors

Research output: Contribution to journalReview article

1 Scopus citations


18F-FDG PET/CT has been described as an accurate tool for initial diagnosis of pancreatic adenocarcinoma. It differentiates benign from malignant causes; detects local and, especially, distant spread of disease; and is a very good predictor of patient prognosis. Pancreatic neuroendocrine tumors are rare tumors that originate from the islet cells of the pancreas. Currently, 68Ga-DOTA-labeled somatostatin analogs are considered the best modality for detection of well-differentiated neuroendocrine tumors. 18F-FDG PET/CT has a role in patients with poorly differentiated tumors. Recent studies have demonstrated improved survival in patients with metastatic neuroendocrine tumors treated with radiolabeled somatostatin analogs.

Original languageEnglish (US)
Pages (from-to)407-421
Number of pages15
JournalPET Clinics
Issue number4
Publication statusPublished - Oct 1 2017



  • Pancreatic adenocarcinoma
  • Pancreatic cancer
  • Pancreatic neuroendocrine tumor
  • PET
  • PET/CT

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this